The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis.
Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Sun W, Sandor V, Kantarjian HM.
Verstovsek S, et al. Among authors: mesa ra.
Br J Haematol. 2013 May;161(4):508-16. doi: 10.1111/bjh.12274. Epub 2013 Mar 11.
Br J Haematol. 2013.
PMID: 23480528
Free PMC article.
Clinical Trial.